Pierre Raboisson serves as Senior Vice President, Head of Discovery at Galapagos since June 2022. Pierre has over 20 years of experience in medicinal chemistry and drug discovery. Prior to joining Galapagos, he was Executive Vice President at Aligos Therapeutics, where he established the European site and delivered a number of drug candidates in the field of Hepatitis B, NASH, Covid-19 and hepatocellular carcinoma.
Until 2018, Pierre was Vice President and Research Fellow of Janssen Pharmaceutical Companies of Johnson & Johnson, where he was the Global European Head of Medicinal Chemistry having responsibilities across four therapeutic areas: Infectious Diseases, Oncology, Neuroscience and Global Public Health.
From September 2016-September 2018, he served as Vice President and Head of European Research for the Infectious Diseases Therapeutic area of Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to that, Pierre had increasing responsibilities at Tibotec Therapeutics, which became Janssen Therapeutics, Division of Janssen Products, LP in 2011. Dr. Raboisson received his Pharmacist Degree and Ph.D. in Medicinal Chemistry from the University Louis Pasteur from Strasbourg, France and had his post-doctoral training at ArQule Inc, Woburn.